There are several large diabetes studies that have been conducted (VADT, ACCORD, and ADVANCE). All these studies showed that the pharmaceuticals had limitations in protection against cardiovascular risk and a high percentage of subjects were not meeting either the ADA or the AACE guidelines of control. In our 6 month study subjects on oral medications were not meeting recommended guidelines at inclusion but after 6 months of supplementation with Diabetinol they were able to achieve target goals.

With “Structure Function” claims escalating at the FTC/ FDA clinical studies are increasingly more critical. The Sugar Management category has very little human clinical proof to back Nutra claims. We mostly see rat studies and sometimes in house tests at various locations. Diabetinol ™ has the credentials to make very strong claims to support the label claims you might demand.